木丹颗粒联合贝前列素钠、依帕司他治疗糖尿病周围神经病变的疗效观察

摘要

OBJECTIVE:To evaluate the clinical efficacy and safety of Mudan particles plus beraprost and epalrestat for diabetic peripheral neuropathy .METHODS: 152 patients with diabetic peripheral neuropathy were randomly divided into two groups of 76 cases each .The patients in the control group were orally administered with beraprost(40 μg) t.i.d plus epalrestat (50 mg) t.i.d alone, while the patients in the treatment group were orally administered with add-on Mudan particles (7 g) t.i.d.After treatment of 3 weeks ( one course of treatment ), the improvement in clinical symptoms and EMG in the two groups were evaluated .RESULTS:The total effective rates in the treatment group and the control group were 93.4%(71/76) and 78.9%(60/76), and the differences between the two groups were statistically significant ( P <0.05 ) .After treatment, the motor nerve conduction velocity and the sensory nerve conduction velocity of the median nerve and the common peroneal nerve in both groups were significantly improved compared with before treatment ( P<0.05 ) , with the treatment group showing better improvement than in the control group ( P <0.01 ) .No significant adverse reactions were noted in two groups .CONCLUSIONS: Mudan particles added to beraprost and epalrestat is as safe as beraprost plus epalrestat alone yet the former is more effective than the latter in treating diabetic peripheral neuropathy .%目的：观察木丹颗粒联合贝前列素钠、依帕司他治疗糖尿病周围神经病变的临床疗效及安全性。方法：将152例糖尿病周围神经病变患者，以随机数字表法分为2组各76例。对照组患者口服贝前列素钠40μg、1日3次＋依帕司他50 mg、1日3次，治疗组患者在对照组的基础上加用木丹颗粒7g、1日3次、口服。2组均以3周为1个疗程，观察治疗前、后2组患者的临床症状及肌电图改善情况。结果：治疗组、对照组患者总有效率分别为93.4％（71／76）、78.9％（60／76），差异有统计学意义（P＜0.05）。治疗后，2组患者正中神经和腓总神经的运动神经传导速度和感觉神经传导速度较治疗前均有明显改善，差异有统计学意义（ P＜0.05）；且治疗组较对照组改善更明显，差异有统计学意义（P＜0.01）。2组患者均未见明显的不良反应。结论：木丹颗粒联合贝前列素钠、依帕司他治疗糖尿病周围神经病变的疗效优于贝前列素钠、依帕司他联合治疗，且无明显不良反应。